You are here

RodTurner's blog

IRA Investing Brings More and Higher-Value Investors to InSitu Biologics Reg A+ Capital Raise

When InSitu Biologics, Inc. opened its Reg A+ pre-revenue equity offering to IRA investors in 2018, company President and CEO Jim Segermark quickly realized he was attracting new investors to the capital raise that wouldn’t have invested without the IRA option.

“All of our IRA investors have transferred in; no one has used new money to open their IRA account,” Segermark said. “We wouldn’t have gotten those investments if they hadn’t been able to use their IRA money.” 

Pages

Subscribe to RSS - RodTurner's blog